Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Inspire Medical Systems, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
-
Freshworks Appoints Kady Srinivasan as Chief Marketing Officer
-
Form 8.3 - [IDOX PLC - 06 01 2026] - (CGWL)
-
Artios to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Evaxion to present 2026 company milestones at Biotech Showcase conference in San Francisco next week
-
Egle Therapeutics Appoints John Celebi as Chief Executive Officer
-
Emergent BioSolutions to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
-
Form 8.3 - [IQE PLC - 06 01 2026] - (CGAML)
-
Form 8.3 - [IDOX PLC - 06 01 2026] - (CGAML)
-
Form 8.3 - Inspecs Group Plc
-
KLC ALERT: Shareholder Justice Law Firm Julie & Holleman LLP Is Investigating KinderCare’s Directors and Officers for Potential Wrongdoing
-
XPO Renews Support for Susan G. Komen® 3-Day Walks as Official Transportation Partner
-
Form 8.3 - Frenkel Topping Group Plc
-
Form 8.3 - 1Spatial Plc
-
Capital Power extends its Arlington Valley tolling agreement to 2038 and increases its summer capacity by 35 MWs, enhancing reliability and long-term value
-
FibroGen Rebrands as Kyntra Bio to Reflect a New Era of Focus and Momentum
-
BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™
-
Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs
-
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
-
Hypercharge Announces Hypercorp Energy Solutions to Orchestrate the Future of Energy Management
-
Creative Realities Launches Digital Drive-Thru 2.0, a Modular, Scalable Solution Designed to Improve Drive-Thru Efficiency and Flexibility
-
Anterix Appoints Ross Spero as Chief Product Officer
-
Sotera Health to Present at the 44th Annual J.P. Morgan Healthcare Conference
-
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy
-
Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference
-
Social Media Influence in the Exam Room: National Survey About Medical Testing Reveals Changing Patient Expectations
-
Stardust Power Engages 38 North Solutions To Support Federal Government Relations
-
FreshBooks and Kick Bring Self-Driving Bookkeeping to U.S. Small Businesses
-
TappAlpha and Tuttle Capital Launch the T² Lift™ Series with TSYX and TDAX — Light-Leverage Versions of TSPY and TDAQ Designed to Offer 30% More Exposure to Growth + Income
-
Digital Currency X Technology Expands Digital Asset Strategy Through Token Staking with EdgeAI Foundation
-
Glucose Health, Inc. Board Members Confirm Participation in Preferred Share Conversion at 85% Premium to Market and Introduce New Revenue Growth Strategy
-
Paul Hollis Confirmed as 41st Director of the United States Mint
-
Kraig Biocraft Laboratories Takes Possession of Three Strategic Mulberry Fields Advancing Massive Spider Silk Production Ramp-Up
-
Oroco Announces Bought Deal Financing Led by Canaccord Genuity
-
Clarios Launches Trailer Battery Manager to Expand Connected Services Platform
-
First Diamond Drill Program Commences at Nobel’s Flagship Cuprita Copper Project, Antofagasta Region, Chile
-
Automotive Industry Veteran Jacob Tilzer and Accrual Equity Partners Launch Gemba Automotive in Arizona
-
Emerita Intersects 2.1m Grading 1.6% Copper, 0.85 g/t Gold, 32.11 g/t Silver and 1.4m Grading 5.8% Copper, 4.89 g/t Gold and 51.0 g/t Silver at El Cura
-
Monte Rosa Therapeutics Announces Positive Interim Phase 1 Data of MRT-8102 Demonstrating Profound CRP Reductions in Elevated CVD-risk Subjects
-
EyePoint Reports Corporate Update and Anticipated Pivotal Milestones for 2026
-
Kamada Provides 2026 Annual Guidance of $200 - $205 Million in Revenues and $50 - $53 Million of Adjusted EBITDA, Representing Double-Digit Growth and Affirms 2025 Financial Guidance
-
Automotive innovation through open collaboration: momentum builds around open source software as a key driver of efficiency and success
-
BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®
-
Rezolute Provides Insights from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism and Shares Findings from its Expanded Access Program in Tumor Hyperinsulinism
-
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
-
BitMart Exchange Announces Partnership with Hit TV-Reality Show CryptoKnights for Season 2
-
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
-
Barrick to Report Full Year and Fourth Quarter 2025 Results on February 5
